Skip to main content

Table 3 Correlation of FGF-23 with categorical characteristics

From: FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI

Items

FGF-23 (pg/mL), median (IQR)

P value

Gender

 

0.946

 No

736.6 (634.3–808.5)

 

 Yes

736.5 (608.0–905.8)

 

Current smoke

 

0.700

 No

727.9 (608.2–907.5)

 

 Yes

752.0 (661.8–855.1)

 

Hypertension

 

0.167

 No

706.2 (571.8–887.1)

 

 Yes

748.1 (641.0–886.0)

 

Diabetes mellitus

 

0.201

 No

720.9 (587.0–862.8)

 

 Yes

749.6 (657.8–907.5)

 

Hypercholesteremia

 

< 0.001

 No

582.7 (482.5–694.4)

 

 Yes

798.6 (720.0–988.4)

 

Hyperuricemia

 

0.022

 No

715.8 (575.8–901.7)

 

 Yes

766.4 (672.5–870.8)

 

Family history of CAD

 

0.022

 No

729.5 (603.5–848.3)

 

 Yes

781.4 (667.5–1005.0)

 

Multivessel artery lesions

 

0.061

 No

691.2 (579.7–795.2)

 

 Yes

750.2 (630.4–914.6)

 

Patients with two target lesions

 

0.880

 No

746.5 (630.4–876.7)

 

 Yes

721.2 (581.9–892.1)

 

Target lesion at LAD

 

0.628

 No

720.3 (622.4–909.9)

 

 Yes

748.9 (603.7–876.9)

 

Target lesion at LCX

 

0.496

 No

741.1 (609.5–896.5)

 

 Yes

734.3 (616.5–886.0)

 

Target lesion at RCA

 

0.306

 No

749.6 (636.5–863.3)

 

 Yes

698.1 (592.8–912.3)

 
  1. Boldface represented P < 0.05
  2. FGF-23 fibroblast growth factor 23, IQR interquartile range, CAD coronary artery disease, LAD left anterior descending branch, LCX left circumflex artery, RCA right coronary artery